Alnylam charts five-year plan as sales of key drug miss expectations
statnews.com••general
Key Points:
- Alnylam announced a five-year growth and innovation plan called Alnylam 2030, aiming to build on its recent successes in gene-silencing therapies.
- CEO Yvonne Greenstreet emphasized the company’s sustainable innovation engine combined with a strong commercial organization as key drivers for long-term growth.
- The company plans to lead in the disease treated by its top-selling drug, Amvuttra, and develop two additional medicines targeting different diseases with potential annual sales exceeding $1 billion each.
- Alnylam intends to invest 30% of its sales into research and development while growing annual sales by 25% and maintaining a 30% operating margin, excluding one-time costs.
- Despite these ambitious goals, the
